Moreover, in multiple myeloma, copy number amplification of chromosome 1q21, which contains both ADAR1 and interleukin-6 receptor (IL-6R) gene loci, is associated with a poor prognosis, while ADAR1 knockdown alters sensitivity to lenalidomide [100]. This evidence concerns the gene ADAR and plasma cell myeloma.